Skip to main content
Home
This website is for UK healthcare professionals.
  • Contact

Search form

  • Home
  • Cardiovascular
  • Diabetes
    • Trajenta®(linagliptin)
    • Jardiance®(empagliflozin)
  • IPF
    • OFEV®(nintedanib esilate)
  • Oncology
    • GIOTRIF®(afatinib dimaleate)
    • VARGATEF®(nintedanib esilate)
  • Respiratory
    • COPD
      • Spiolto® Respimat®(tiotropium & olodaterol)
      • Spiriva® Respimat®(tiotropium)
    • Asthma
      • Spiriva® Respimat®(tiotropium)
  • Thrombosis
    • Actilyse®(alteplase)
    • Actilyse® Cathflo® 2mg(alteplase)
  • Healthcare Commissioners
    • Tools and Resources
    • Publications
    • Training
  • Contact
  • Home
  • Thrombosis
  • Actilyse Cathflo

Responsive Banner

  • Interactive

    Managing thrombotic CVAD occlusions

    An educational tool for treating CVAD-related thrombosis

  • Prescribing Information

    Actilyse®
    (alteplase)
    Actilyse® Cathflo® 2mg
    (alteplase)
    GIOTRIF®
    (afatinib dimaleate)
    Jardiance®
    (empagliflozin)
    Jentadueto®
    (linagliptin/metformin HCI)
    OFEV®
    (nintedanib esilate)
    Pradaxa®
    (dabigatran etexilate)
    Praxbind®
    (idarucizumab)
    Spiolto® Respimat®
    (tiotropium & olodaterol)
    Spiriva®
    (tiotropium)
    Spiriva® Respimat®
    (tiotropium)
    Striverdi® Respimat®▼
    (olodaterol)
    Synjardy®
    (empagliflozin/metformin hydrochloride)
    Trajenta®
    (linagliptin)
    VARGATEF®
    (nintedanib esilate)
  • Video

    Living with dialysis video

  • Video

    How to administer Actilyse® Cathflo®

    Watch this short video

  • Video

    Background to CVAD use

  • Video

    Types of CVAD occlusions

  • Video

    Actilyse® Cathflo® (alteplase) mode of action

  • Article

    Actilyse® Cathflo® dosing and administration

  • Interactive

    Thrombotic occlusion formation 

    Click to discover more

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

usc head image

Information intended for:

UK HEALTHCARE PROFESSIONALS

Click here if you are a UK Healthcare professional and would like more information on Boehringer Ingelheim Medicines


UK HEALTHCARE PROFESSIONAL WEBSITE

Information intended for:

MEMBERS OF THE PUBLIC, CARERS & PATIENTS

Click here if you are a member of the public, carer or patient and would like more information on Boehringer Ingelheim Medicines


MORE INFORMATION ON BOEHRINGER INGELHEIM MEDICINES

Reporting adverse events

Adverse events should be reported. Reporting form and information can be found at www.mhra.gov.uk/yellowcard

Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

Reporting side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in package leaflet.

You can also report side effects directly to the Yellow Card scheme of www.mhra.gov.uk/yellowcard

By reporting side effects you can help provide more information on the safety of the medicine.

For more information, or to access the current prescriber guides and summary of product characteristics, please visit www.medicines.org.uk/emc

NP-UK-100172 V1 – March 2019

  • Accessibility Statement
  • Privacy and Cookie Policy
  • Terms of Use
  • Product Information
© 1999-2018 Boehringer Ingelheim GmbH All rights reserved.

PC-UK-101782 date of prep July 2019